- Details
- Alicia Morgans is joined by Neal Shore, who provides his perspective on the phase 3 ARASENS data for patients with metastatic hormone-sensitive prostate cancer, which demonstrates the superiority in terms of survival and numerous other secondary endpoints of triplet versus doublet therapy. In ARASENS, darolutamide + androgen-deprivation therapy (ADT) + docetaxel significantly reduced risk of death...
|
- Details
- Neal Shore joins Alicia Morgans in discussing the approval of NUBEQA® (darolutamide) in the metastatic hormone-sensitive setting in combination with docetaxel on ADT. Drs. Shore and Morgans speak about the clinical implications of this approval from a urologist's perspective. The approval was based on the overall survival data Matthew Smith presented at ASCO GU 2022 and the 32% reduction in mortal...
|
- Details
- In a conversation with Alicia Morgans, Professor Bertrand Tombal provides a synopsis of metastatic subtypes in the ARASENS trial outcomes. The ARASENS trial investigated the benefit of darolutamide by comparing ADT plus docetaxel and darolutamide versus a placebo group. Tombal and Morgans wrap up the conversation by acknowledging the pragmatic and effective treatment recommendations that resulted...
|
- Details
- Drs Charles Ryan and Alicia Morgans discuss the approval of NUBEQA® (darolutamide) tablets, for oral use for metastatic hormone-sensitive prostate cancer (mHSPC). The FDA has approved darolutamide in combination with docetaxel for adult patients with mHSPC. This regulatory decision is based on findings from the phase 3 ARASENS trial. ARASENS is a randomized phase 3 trial of darolutamide versus pla...
|
- Details
- Fred Saad joins Alicia Morgans in discussing the association between PSA response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial. In the ARASENS trial, the combination of darolutamide plus ADT and docetaxel significantly prolonged the time to PSA progression, and more patients receiving darolutamide vs placebo achieved...
|
- Details
- Cora Sternberg joins Alicia Morgans in a discussion on the treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) highlighting the ARASENS trial. The treatment landscape for mHSPC has become increasingly complex during the last several years. The ARASENS study along with PEACE-1 demonstrated that in patients eligible for treatment with chemotherapy, the addition of abiraterone...
|
- Details
- Alicia Morgans is joined by Tomasz Beer for a discussion on the ARASENS trial. Recently presented at GU ASCO 2022, the ARASENS trial is an international, double-blind, phase 3 study that enrolled patients with metastatic hormone-sensitive prostate cancer (mHSPC) and ECOG performance status 0 or 1. The most important finding was androgen deprivation therapy (ADT) plus docetaxel plus darolutamide pr...
|
- Details
- Alicia Morgans is joined by Bertrand Tombal who provides a European perspective highlighting prostate cancer data we have seen so far this year starting with the ARASENS and PEACE-1 data. Dr. Tombal's discussion highlights key points for the community to focus on including the messages around maximal androgen blockade and PARP inhibitors. Biographies: Bertrand Tombal, MD, PhD, Chairman of the Depa...
|
- Details
- Fred Saad, Bertrand Tombal, and Neal Shore join Alicia Morgans in a discussion on the results of the ARASENS trial which examined darolutamide in combination with docetaxel and ADT compared to docetaxel and ADT. They discuss the trial design, its endpoints, how it impacts practice in Canada, the US, and in Europe, and the ideal patient population for this treatment. Biographies: Neal Shore, MD, FA...
|
- Details
- Christopher Wallis and Zachary Klaassen highlight the New England Journal of Medicine publication on the international, phase 3 ARASENS trial. The primary analysis involved 1306 patients (651 in the darolutamide group and 655 in the placebo group); 86.1% of the patients had disease that was metastatic at the time of the initial diagnosis. At the data cutoff date for the primary analysis (October 2...
|
